Mutant TP53 stabilized by heat shock protein 90 (HSP90) is a novel target in oncology.
The open-label randomized phase II GANNET53 trial is the first to evaluate the HSP90 inhibitor Ganetespib (G) with Paclitaxel (P) in platinum-resistant epithelial ovarian cancer (EUDRACT 2013-003868-31; EU FP7 #602602).
